Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2019 | Treating VOD/SOS: next steps

Paul Richardson • 24 Mar 2019

EBMT 2019

General Defibrotide

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, speaks at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany. Here, Prof. Richardson discusses the next steps going forward for the treatment of veno-oclusive disease/sinusoidal obstruction syndrome (VOD/SOS). There is hope that earlier intervention and preventative therapy will be the next rational step for improving outcomes in the future.
Here, Prof. Richardson discusses the next steps going forward for the treatment of veno-oclusive disease/ sinusoidal obstruction syndrome (VOD/SOS). There is hope that earlier intervention and preventative therapy will be the next rational step for improving outcomes in the future.

Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma

Paul Richardson • 29 Sep 2023

ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma

Paul Richardson • 29 Sep 2023

Session highlights: managing the aging population in myeloma & promising treatment options

Paul Richardson • 29 Sep 2023

Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial

Paul Richardson • 12 May 2023

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives

Claire Horgan • 15 Apr 2024